Nicholas Van Niel
About Nicholas Van Niel
Nicholas Van Niel is the Vice President at Analysis Group in Boston, Massachusetts, with a background in economics, mathematics, and Chinese.
Vice President at Analysis Group
Nicholas Van Niel is currently serving as Vice President at Analysis Group in Boston, Massachusetts, United States. He has been in this position since 2022. His tenure at Analysis Group reflects a steady climb through various roles, including Manager and Associate, showcasing his extensive experience with the company over several years.
Previous Roles at Analysis Group
Prior to becoming Vice President, Nicholas Van Niel held multiple positions at Analysis Group. From 2019 to 2021, he served as Manager in the Greater Boston Area, and from 2016 to 2018, he was an Associate in Boston. His journey with Analysis Group began as a Senior Analyst from 2010 to 2014. These roles have provided him with a robust background in economic and financial analysis.
Experience at Nike and TrustLayers
In 2015, Nicholas Van Niel worked as a Project Manager at Nike in Beaverton, OR. The same year, he also served in Business Development at TrustLayers in the Greater Boston Area. These roles attest to his versatility and ability to manage various projects across different industries.
Education and Background
Nicholas Van Niel earned his Master of Business Administration (MBA) from MIT Sloan School of Management, where he studied from 2014 to 2016. He also holds a Bachelor of Arts (BA) from Colby College, where he studied Economics, Mathematics, and Chinese. Additionally, he studied Chinese at the Harbin Institute of Technology, which underscores his diverse academic background.
Co-Authored Article on CDC Opioid Prescribing Guidelines
Nicholas Van Niel co-authored an article that analyzed the CDC's opioid prescribing guidelines. The study assessed changes in opioid prescription patterns before and after the 2016 guidelines. It particularly focused on prescriptions at or above 90 morphine milligram equivalent (MME) and prescriptions for longer than a seven-day period for drugs like oxycodone and hydrocodone. This work reflects his contributions to important public health research.